{"id":"placebo-tiotropium","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Dry mouth"},{"rate":"1-3","effect":"Tremor"},{"rate":"2-5","effect":"Headache"},{"rate":"1-2","effect":"Urinary retention"},{"rate":"1-2","effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tiotropium binds to M3 muscarinic receptors on airway smooth muscle cells, preventing acetylcholine-induced bronchoconstriction. This results in sustained airway relaxation and improved airflow. The placebo control in this formulation is used for comparative efficacy assessment in clinical trials.","oneSentence":"Tiotropium is a long-acting anticholinergic bronchodilator that blocks muscarinic receptors in airway smooth muscle to produce sustained bronchodilation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:28.799Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"},{"name":"Asthma (in combination with inhaled corticosteroids)"}]},"trialDetails":[{"nctId":"NCT02175342","phase":"PHASE2","title":"Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":202},{"nctId":"NCT05165485","phase":"PHASE4","title":"Phase 4 COPD and Suboptimal Inspiratory Flow Rate","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2022-01-07","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":404},{"nctId":"NCT01152450","phase":"PHASE2","title":"A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-07","conditions":"Asthma","enrollment":94},{"nctId":"NCT06679465","phase":"PHASE4","title":"Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response","status":"NOT_YET_RECRUITING","sponsor":"University of Saskatchewan","startDate":"2025-01-01","conditions":"Asthma Bronchiale","enrollment":10},{"nctId":"NCT04061161","phase":"PHASE4","title":"Anti-inflammatory Effects of Tiotropium in Patients with Stable COPD","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2019-08-19","conditions":"COPD","enrollment":37},{"nctId":"NCT05986591","phase":"PHASE3","title":"Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Xiromed LLC","startDate":"2022-08-17","conditions":"COPD","enrollment":335},{"nctId":"NCT00144196","phase":"PHASE4","title":"12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-03-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":224},{"nctId":"NCT00274508","phase":"PHASE3","title":"Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-10-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":261},{"nctId":"NCT02242266","phase":"PHASE2","title":"Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-07-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":121},{"nctId":"NCT00668772","phase":"PHASE3","title":"Tiotropium/Salmeterol Inhalation Powder in COPD","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":207},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT00662740","phase":"PHASE3","title":"Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":220},{"nctId":"NCT05161156","phase":"PHASE3","title":"Bioequivalence Study of Tiotropium Bromide Inhalation Powder","status":"COMPLETED","sponsor":"Phargentis SA","startDate":"2022-03-24","conditions":"COPD","enrollment":306},{"nctId":"NCT05113615","phase":"PHASE4","title":"Regular Use Tiotropium and Tolerance to Bronchoprotection in Mild Asthma","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2021-12-13","conditions":"Asthma","enrollment":12},{"nctId":"NCT02518139","phase":"PHASE3","title":"A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1060},{"nctId":"NCT03095456","phase":"PHASE3","title":"Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2017-03-27","conditions":"Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)","enrollment":207},{"nctId":"NCT04223843","phase":"PHASE4","title":"A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-01-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":213},{"nctId":"NCT02203474","phase":"PHASE2","title":"A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease","status":"WITHDRAWN","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2014-08","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":""},{"nctId":"NCT01176903","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2010-08","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":65},{"nctId":"NCT04648813","phase":"PHASE4","title":"Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2020-11-13","conditions":"Allergic Asthma","enrollment":15},{"nctId":"NCT00528996","phase":"PHASE2","title":"An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-09-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2080},{"nctId":"NCT02872090","phase":"PHASE4","title":"Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2016-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":42},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT03084796","phase":"PHASE2","title":"A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-07-28","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":733},{"nctId":"NCT04780984","phase":"PHASE2","title":"Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Nephron Pharmaceuticals Corporation","startDate":"2020-11-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":116},{"nctId":"NCT03137992","phase":"PHASE3","title":"Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness","status":"COMPLETED","sponsor":"Lupin, Inc.","startDate":"2017-11-21","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":377},{"nctId":"NCT01068613","phase":"PHASE2","title":"Safety and Efficacy of Multiple Doses of QAX028 in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":62},{"nctId":"NCT00532350","phase":"PHASE1","title":"Safety and Tolerability QAT370 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-07","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":22},{"nctId":"NCT03937479","phase":"PHASE2","title":"Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2019-05-01","conditions":"COPD","enrollment":416},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT02586649","phase":"PHASE2","title":"24hr Effects of Tiotropium Bromide in Tetraplegia","status":"COMPLETED","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2014-07","conditions":"Spinal Cord Injury","enrollment":10},{"nctId":"NCT03358147","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2017-12-13","conditions":"Asthma","enrollment":1077},{"nctId":"NCT02845752","phase":"PHASE4","title":"The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2017-03-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":14},{"nctId":"NCT04147572","phase":"NA","title":"Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2019-11-01","conditions":"Healthy Volunteer, COPD","enrollment":200},{"nctId":"NCT04208581","phase":"PHASE3","title":"Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2019-10-08","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Respiratory Failure","enrollment":372},{"nctId":"NCT03673670","phase":"PHASE2","title":"Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2018-07-16","conditions":"COPD","enrollment":79},{"nctId":"NCT00569270","phase":"PHASE4","title":"Dynamic Hyperinflation and Tiotropium","status":"COMPLETED","sponsor":"Gelb, Arthur F., M.D.","startDate":"2006-10","conditions":"COPD","enrollment":30},{"nctId":"NCT00773786","phase":"PHASE4","title":"Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Trinity Health Of New England","startDate":"2008-10","conditions":"COPD","enrollment":20},{"nctId":"NCT03118765","phase":"PHASE2","title":"Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2017-03-24","conditions":"Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)","enrollment":155},{"nctId":"NCT00860938","phase":"PHASE4","title":"Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD","status":"COMPLETED","sponsor":"Cantonal Hosptal, Baselland","startDate":"2007-04","conditions":"COPD","enrollment":90},{"nctId":"NCT02059434","phase":"PHASE1","title":"Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-09-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD), Asthma","enrollment":55},{"nctId":"NCT02567214","phase":"PHASE4","title":"Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Laval University","startDate":"2016-06","conditions":"COPD","enrollment":50},{"nctId":"NCT03976713","phase":"PHASE3","title":"Bufei Yishen Granule for Reducing Acute Exacerbation in GOLD Stage 3 or 4 COPD","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2019-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":348},{"nctId":"NCT02066298","phase":"PHASE3","title":"Steroids In Eosinophil Negative Asthma","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2014-07","conditions":"Asthma","enrollment":295},{"nctId":"NCT00996697","phase":"PHASE4","title":"Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2006-10","conditions":"COPD","enrollment":23},{"nctId":"NCT03028142","phase":"PHASE2","title":"The Effects of RPL554 in Addition to Tiotropium in COPD Patients","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2017-01","conditions":"Chronic Obstructive Pulmonary Disease Moderate","enrollment":30},{"nctId":"NCT03425617","phase":"PHASE4","title":"Effects of Dual Bronchodilator Treatment on Cardiopulmonary Interactions in COPD","status":"COMPLETED","sponsor":"Queen's University","startDate":"2017-01-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":25},{"nctId":"NCT02796677","phase":"PHASE3","title":"AMPLIFY - D6571C00001 Duaklir USA Phase III Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-07-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1595},{"nctId":"NCT02573155","phase":"PHASE1","title":"Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10","conditions":"Asthma (Part 1), COPD (Part 2)","enrollment":134},{"nctId":"NCT01662986","phase":"PHASE4","title":"Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-08-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":79},{"nctId":"NCT01663987","phase":"PHASE4","title":"Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-08-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":79},{"nctId":"NCT02172391","phase":"PHASE3","title":"Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":81},{"nctId":"NCT02172443","phase":"PHASE3","title":"Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":50},{"nctId":"NCT02172794","phase":"PHASE3","title":"Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":48},{"nctId":"NCT02683109","phase":"PHASE4","title":"Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-03-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":221},{"nctId":"NCT01426009","phase":"PHASE2","title":"Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study","status":"COMPLETED","sponsor":"Sunovion Respiratory Development Inc.","startDate":"2011-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":140},{"nctId":"NCT02257385","phase":"PHASE3","title":"Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":967},{"nctId":"NCT02207829","phase":"PHASE3","title":"A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1017},{"nctId":"NCT00122434","phase":"PHASE2","title":"Dose Finding Study in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":389},{"nctId":"NCT00157235","phase":"PHASE3","title":"Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":234},{"nctId":"NCT00152984","phase":"PHASE4","title":"Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-12","conditions":"Pulmonary Disease, Chronic Obstructive, Asthma","enrollment":472},{"nctId":"NCT01372410","phase":"PHASE2","title":"A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":163},{"nctId":"NCT01124422","phase":"PHASE4","title":"Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":255},{"nctId":"NCT00950807","phase":"PHASE2","title":"GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":176},{"nctId":"NCT01566773","phase":"PHASE2","title":"PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2012-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":140},{"nctId":"NCT00279019","phase":"PHASE1","title":"Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":31},{"nctId":"NCT00555022","phase":"PHASE1","title":"Effect of GSK1160724 In Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-12-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":21},{"nctId":"NCT00515502","phase":"PHASE2","title":"Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-21","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":24},{"nctId":"NCT02382510","phase":"PHASE2","title":"Multiple Ascending Dose Study of TRN-157 in Stable Mild and Moderate Asthmatics","status":"COMPLETED","sponsor":"Theron Pharmaceuticals, Inc.","startDate":"2015-04","conditions":"Asthma","enrollment":59},{"nctId":"NCT01085045","phase":"PHASE2","title":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2010-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":118},{"nctId":"NCT02165826","phase":"PHASE3","title":"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1323},{"nctId":"NCT01715311","phase":"PHASE4","title":"Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":""},{"nctId":"NCT02347072","phase":"PHASE3","title":"24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-02-01","conditions":"COPD","enrollment":80},{"nctId":"NCT01854645","phase":"PHASE3","title":"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":2103},{"nctId":"NCT00478738","phase":"PHASE2","title":"A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":82},{"nctId":"NCT00857766","phase":"PHASE4","title":"A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":249},{"nctId":"NCT02085161","phase":"PHASE3","title":"To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":304},{"nctId":"NCT01462929","phase":"PHASE3","title":"Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":414},{"nctId":"NCT00868231","phase":"PHASE2","title":"Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-03","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":30},{"nctId":"NCT00424268","phase":"PHASE3","title":"Effect of Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Tiotropium: The HELIOS Study (BY217/M2-128)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":743},{"nctId":"NCT00784550","phase":"PHASE4","title":"A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":342},{"nctId":"NCT00435760","phase":"PHASE3","title":"Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":115},{"nctId":"NCT01762800","phase":"PHASE4","title":"Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":407},{"nctId":"NCT00539825","phase":"PHASE1","title":"Effect of GSK704838 In Healthy Volunteers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":20},{"nctId":"NCT00422604","phase":"PHASE2","title":"Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":60},{"nctId":"NCT01525615","phase":"PHASE3","title":"A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":404},{"nctId":"NCT01455129","phase":"PHASE4","title":"Tiotropium In Early Chronic Obstructive Pulmonary Disease Patients in China","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2011-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":841},{"nctId":"NCT01634139","phase":"PHASE3","title":"Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-07","conditions":"Asthma","enrollment":403},{"nctId":"NCT01610037","phase":"PHASE3","title":"Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1215},{"nctId":"NCT02622243","phase":"PHASE4","title":"Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2015-11","conditions":"Asthma","enrollment":13},{"nctId":"NCT01959516","phase":"PHASE4","title":"Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-02","conditions":"COPD","enrollment":124},{"nctId":"NCT00999908","phase":"PHASE3","title":"Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":54},{"nctId":"NCT01012765","phase":"PHASE3","title":"Effect of Indacaterol on Inspiratory Capacity (IC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":173},{"nctId":"NCT01969721","phase":"PHASE3","title":"Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":229},{"nctId":"NCT01634152","phase":"PHASE3","title":"Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-07","conditions":"Asthma","enrollment":401},{"nctId":"NCT02006732","phase":"PHASE3","title":"Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":809},{"nctId":"NCT01964352","phase":"PHASE3","title":"Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":813},{"nctId":"NCT01533935","phase":"PHASE3","title":"Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":291},{"nctId":"NCT01533922","phase":"PHASE3","title":"Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":295}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":28,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Spiriva"],"phase":"marketed","status":"active","brandName":"Placebo + Tiotropium","genericName":"Placebo + Tiotropium","companyName":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","companyId":"irccs-azienda-ospedaliero-universitaria-di-bologna","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tiotropium is a long-acting anticholinergic bronchodilator that blocks muscarinic receptors in airway smooth muscle to produce sustained bronchodilation. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy, Asthma (in combination with inhaled corticosteroids).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}